Literature DB >> 19596949

Clinical characteristics of laryngeal cancer in BRCA-1 mutation carriers.

Ewa Jaworowska1, Czesława Tarnowska, Jakub Lubiński, Pablo Serrano-Fernández, Tomasz Huzarski, Bogdan Górski, Bartlomiej Masojć, Jerzy Jakubiszyn, Aleksandra Korytowska, Andrzej Kram, Jerzy Rabczynski, Jan Lubiński.   

Abstract

BACKGROUND: The aim of this study was to analyze the occurrence of clinical features characteristic of breast cancer type 1 susceptibility protein (BRCA-1)-dependent tumors in a series of BRCA-1 mutation carriers with laryngeal cancer. PATIENTS AND METHODS: The clinical features of five laryngeal cancer patients with BRCA-1 mutations registered in our center were analyzed for: sex, age at diagnosis, age at operation, tumor size and localization, histopathological subtype and grading, lymph node and distant metastases, mode of treatment and long term results of the therapy.
RESULTS: The five patients were all men, with an average age at diagnosis of 52.4 years. The majority of the patients had clinical features typical of BRCA-1-dependent tumors: four out of the five patients had advanced staging at the time of diagnosis and in three of them the disorder disseminated within one year of follow-up.
CONCLUSION: Since laryngeal carcinomas in men with BRCA-1 mutations show clinical features characteristic of BRCA-1 dependent tumors, it is reasonable to consider treatment modifications appropriate for this sub-group of tumors.

Entities:  

Mesh:

Year:  2009        PMID: 19596949

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  2 in total

1.  Squamous cell carcinoma of the oral cavity in nonsmoking women: a new and unusual complication of chemotherapy for recurrent ovarian cancer?

Authors:  Timothy L Cannon; Dominic W Lai; David Hirsch; Mark Delacure; Andrea Downey; Alexander R Kerr; Michael Bannan; Eleni Andreopoulou; Tamar Safra; Franco Muggia
Journal:  Oncologist       Date:  2012-05-23

2.  Oral squamous cell carcinoma in a patient treated with long-term pegylated liposomal doxorubicin for recurrent ovarian cancer.

Authors:  Matteo Pezzoli; Maurizio Bona Galvagno; Guido Bongioannini
Journal:  BMJ Case Rep       Date:  2015-01-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.